CytoMed Flags Going Concern, Books S$1M Director Loan in H1 2026 Report
GDTC sits 35% above its 52-week low of $0.68 on light trading volume (0.4× avg).
Summary
CytoMed Therapeutics reported a reduced H1 2026 net loss of S$1.79 million, but disclosed going concern language and a new S$1 million director loan.
Key Events · Earnings and Guidance · GDTC
-
Going Concern Disclosure
Negative operating cash flow of S$1,645,739 and cash of S$1,458,764 as of June 30, 2026; management believes resources are sufficient for about the next year.
-
New S$1M Director Loan
On September 29, 2026, the company entered into a shareholder loan agreement with a director for S$1 million at 2.75% per annum, six-month tenure.
-
H1 2026 Net Loss
Net loss of S$1.79 million (US$1.39 million), a 20.1% reduction from S$2.25 million in H1 2025.
-
ATM Program Update
99,123 ordinary shares sold under the US$4.30 million ATM Sales Agreement for gross proceeds of US$237,550.
Analysis · GDTC · Life Sciences
The interim financials carry a going concern disclosure: negative operating cash flow of S$1.65 million and only S$1.46 million in cash as of June 30, 2026. Management believes current resources are sufficient for about the next year, but the disclosure itself is a red flag. A new S$1 million shareholder loan with a director was signed on September 29, 2026, at 2.75% per annum, providing short-term liquidity while adding related-party debt. The ATM program has sold 99,123 shares for US$237,550, a modest draw on the US$4.30 million facility.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37% of the 992 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GDTC was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.5M. The 52-week trading range was $0.68 to $3.68. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.